- Home
- ORKA vs TRVI Comparison
ORKA vs TRVI Comparison
Compare ORKA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- TRVI
- Stock Information
- Founded
- ORKA 2004
- TRVI 2011
- Country
- ORKA United States
- TRVI United States
- Employees
- ORKA N/A
- TRVI N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ORKA Health Care
- TRVI Health Care
- Exchange
- ORKA Nasdaq
- TRVI Nasdaq
- Market Cap
- ORKA 1.2B
- TRVI 1.1B
- IPO Year
- ORKA N/A
- TRVI 2019
- Fundamental
- Price
- ORKA $27.70
- TRVI $10.50
- Analyst Decision
- ORKA Strong Buy
- TRVI Strong Buy
- Analyst Count
- ORKA 8
- TRVI 9
- Target Price
- ORKA $44.38
- TRVI $20.72
- AVG Volume (30 Days)
- ORKA 472.9K
- TRVI 1.7M
- Earning Date
- ORKA 11-12-2025
- TRVI 11-10-2025
- Dividend Yield
- ORKA N/A
- TRVI N/A
- EPS Growth
- ORKA N/A
- TRVI N/A
- EPS
- ORKA N/A
- TRVI N/A
- Revenue
- ORKA N/A
- TRVI N/A
- Revenue This Year
- ORKA N/A
- TRVI N/A
- Revenue Next Year
- ORKA N/A
- TRVI N/A
- P/E Ratio
- ORKA N/A
- TRVI N/A
- Revenue Growth
- ORKA N/A
- TRVI N/A
- 52 Week Low
- ORKA $5.49
- TRVI $2.36
- 52 Week High
- ORKA $30.51
- TRVI $11.11
- Technical
- Relative Strength Index (RSI)
- ORKA 73.15
- TRVI 62.70
- Support Level
- ORKA $25.11
- TRVI $10.16
- Resistance Level
- ORKA $27.75
- TRVI $10.92
- Average True Range (ATR)
- ORKA 2.14
- TRVI 0.53
- MACD
- ORKA -0.02
- TRVI -0.03
- Stochastic Oscillator
- ORKA 83.24
- TRVI 66.48
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.